AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22214113 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted vest
Number of subjects: 10
Study 22214113 — intervention group
Group type: COMPARATOR
Intervention: Non-weighted vest (Control)
Number of subjects: 10
Study 19193900 — intervention group
Group type: EXPERIMENTAL
Intervention: D(2) receptor agonist bromocriptine
Number of subjects: 0
Study 19193900 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug administration)
Number of subjects: 0
Study 16960939 — intervention group
Group type: EXPERIMENTAL
Intervention: High resolution computed tomography (HRCT) at Time 1 (T1)
Number of subjects: 90
Study 16960939 — intervention group
Group type: EXPERIMENTAL
Intervention: High resolution computed tomography (HRCT) at Time 1 (T1) for patients with FA-SSc
Number of subjects: 90
Study 16960939 — intervention group
Group type: EXPERIMENTAL
Intervention: High resolution computed tomography (HRCT) at Time 1 (T1) for patients with isolated ground-glass opacities
Number of subjects: 90
Study 16960939 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with abnormal HRCT
Number of subjects: 90
Study 16960939 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal initial HRCT
Number of subjects: 90
Study 15343191 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 2.5 mg daily
Number of subjects: 268
Study 15343191 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg daily
Number of subjects: 268
Study 15343191 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (dose > or = 0.06 mg/kg per day)
Number of subjects: 268
Study 15343191 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 268
Study 10943966 — intervention group
Group type: EXPERIMENTAL
Intervention: Lang II Random Dot Stereotest
Number of subjects: 4293
Study 9301693 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide (50 mg once daily) plus LHRH‐A
Number of subjects: 813
Study 9301693 — intervention group
Group type: COMPARATOR
Intervention: Flutamide (250 mg three times daily) plus LHRH‐A
Number of subjects: 813
Study 9301693 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide plus LHRH‐A
Number of subjects: 813
Study 9301693 — intervention group
Group type: COMPARATOR
Intervention: Flutamide plus LHRH‐A
Number of subjects: 813
Study 8359186 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoxamine 0.5% solution
Number of subjects: 20
Study 8359186 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution (mannitol)
Number of subjects: 20
Study 8359186 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine 1% solution
Number of subjects: 20
Study 3734450 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-salt diet
Number of subjects: 0
Study 3734450 — intervention group
Group type: EXPERIMENTAL
Intervention: High-salt diet
Number of subjects: 0
Study 29864710 — intervention group
Group type: EXPERIMENTAL
Intervention: High force mobilization
Number of subjects: 60
Study 29864710 — intervention group
Group type: COMPARATOR
Intervention: Medium force mobilization
Number of subjects: 60
Study 29864710 — intervention group
Group type: COMPARATOR
Intervention: Low force mobilization
Number of subjects: 60
Study 27107634 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EN) via nasojejunal tube initiated within 24 hours of admission
Number of subjects: 214
Study 27107634 — intervention group
Group type: COMPARATOR
Intervention: Nil-by-mouth (NBM) regimen
Number of subjects: 214
Study 24561970 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g/day IV glutamine
Number of subjects: 120
Study 24561970 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g/day enteral glutamine
Number of subjects: 120
Study 24561970 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g/day IV and 15 g/day enteral glutamine
Number of subjects: 120
Study 24561970 — intervention group
Group type: COMPARATOR
Intervention: Only enteral feeding (control group)
Number of subjects: 120
Study 23678503 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic education programme (three-day intervention)
Number of subjects: 120
Study 21122202 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBNP
Number of subjects: 126
Study 17452062 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 131
Study 17452062 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 131
Study 17452062 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (Donepezil and Control)
Number of subjects: 131
Study 17452062 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI measures
Number of subjects: 131
Study 17050753 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Support Group (TSG)
Number of subjects: 97
Study 17050753 — intervention group
Group type: COMPARATOR
Intervention: Usual services
Number of subjects: 97
Study 12790207 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil at target concentrations of 150, 225, and 300 ng mL(‐1)
Number of subjects: 20
Study 12790207 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol added to alfentanil infusion
Number of subjects: 20
Study 12790207 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil target concentration cA0 = 1240 (51) ng mL(‐1) and propofol concentration cP0 = 5.21 (0.36) microg mL(‐1)
Number of subjects: 20
Study 10335220 — intervention group
Group type: EXPERIMENTAL
Intervention: Social intervention through management modification (goal setting and role modeling)
Number of subjects: 0
Study 10335220 — intervention group
Group type: EXPERIMENTAL
Intervention: Architectural modification (physical intervention)
Number of subjects: 0
Study 10335220 — intervention group
Group type: COMPARATOR
Intervention: Control unit with no planned change
Number of subjects: 0
Study 8953336 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate ingestion in Group 1
Number of subjects: 2
Study 8953336 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate ingestion in Group 2
Number of subjects: 2
Study 8953336 — intervention group
Group type: COMPARATOR
Intervention: Active warm-down (AWD)
Number of subjects: 2
Study 8953336 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) in Group 1
Number of subjects: 2
Study 8953336 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) in Group 2
Number of subjects: 2
Study 1773095 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous melatonin (5 mg) at bedtime (2200 hr) for 3 weeks
Number of subjects: 5
Study 1773095 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous melatonin (7 mg at 2100 hr)
Number of subjects: 5
Study 7046937 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol-hydrochlorothiazide combination (n = 47)
Number of subjects: 158
Study 7046937 — intervention group
Group type: COMPARATOR
Intervention: Propranolol alone (n = 51)
Number of subjects: 158
Study 7046937 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide alone (n = 52)
Number of subjects: 158
Study 31879028 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 1201
Study 31879028 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1201
Study 29450523 — intervention group
Group type: EXPERIMENTAL
Intervention: PERC group (n=962)
Number of subjects: 1916
Study 29450523 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=954)
Number of subjects: 1916
Study 26763913 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous tracheostomy within the first five days after intubation
Number of subjects: 380
Study 26763913 — intervention group
Group type: COMPARATOR
Intervention: Ongoing orotracheal intubation with consecutive weaning and extubation, and if failed, percutaneous tracheostomy from day 10 after intubation
Number of subjects: 380
Study 24948511 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (25 mg once daily, orally)
Number of subjects: 1549
Study 24948511 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride (1-4 mg once daily, orally)
Number of subjects: 1549
Study 24948511 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 1549
Study 24948511 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 1549
Study 22406192 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoke Free and Living It© behavioral intervention
Number of subjects: 255
Study 20104069 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20‐40 mg/day)
Number of subjects: 0
Study 20104069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18050186 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal oxygen uptake (VO(2submax))
Number of subjects: 74
Study 18050186 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak VO(2) (VO(2peak))
Number of subjects: 74
Study 18050186 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaerobic power using modified Wingate tests (W(ant))
Number of subjects: 74
Study 18050186 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood Health Assessment Questionnaire (C-HAQ)
Number of subjects: 74
Study 18050186 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised Activity Scale for Kids (ASK)
Number of subjects: 74
Study 18050186 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual Activity Estimation Scale (HAES) total activity score
Number of subjects: 74
Study 18050186 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual Activity Estimation Scale (HAES) very active hours
Number of subjects: 74
Study 16259546 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50-150 mg/day)
Number of subjects: 163
Study 16259546 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine XR (75-225 mg/day)
Number of subjects: 163
Study 12107316 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated stainless-steel Schanz pins
Number of subjects: 46
Study 12107316 — intervention group
Group type: COMPARATOR
Intervention: Standard titanium Schanz pins
Number of subjects: 46
Study 9668744 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteer peer counseling program
Number of subjects: 143
Study 8035044 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient bacteremia
Number of subjects: 60
Study 8035044 — intervention group
Group type: COMPARATOR
Intervention: Sustained bacteremia
Number of subjects: 60
Study 3055720 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x 1 g carnitine orally for one week and 1 x 1 g carnitine for the following 7 days
Number of subjects: 15
Study 3055720 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 15
Study 29754664 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital CV prevention consult (PC; group B)
Number of subjects: 400
Study 29754664 — intervention group
Group type: EXPERIMENTAL
Intervention: PC plus behavioral intervention program (group C)
Number of subjects: 400
Study 29754664 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC; group A)
Number of subjects: 400
Study 29754664 — intervention group
Group type: EXPERIMENTAL
Intervention: PC groups (B and C combined)
Number of subjects: 400
Study 27760869 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (AT)
Number of subjects: 70
Study 27760869 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus education
Number of subjects: 70
Study 24717908 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose remifentanil (0.1 μg/kg/min)
Number of subjects: 14
Study 24717908 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose remifentanil (0.25 μg/kg/min)
Number of subjects: 14
Study 22824930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 445
Study 22824930 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (2.5 mg for the first 3 days followed by 5 mg/day, reduced to 2.5 mg/day on the first postoperative day)
Number of subjects: 445
Study 22824930 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg/day)
Number of subjects: 445
Study 22824930 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 445
Study 22824930 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 445
Study 20422360 — intervention group
Group type: EXPERIMENTAL
Intervention: Rexflavone (Sophorae fructus extract)
Number of subjects: 0
Study 20422360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19127085 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological prophylaxis
Number of subjects: 0
Study 19127085 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic prophylaxis
Number of subjects: 0
Study 19127085 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis
Number of subjects: 0
Study 16398838 — intervention group
Group type: EXPERIMENTAL
Intervention: Goat milk infant formula (GMF)
Number of subjects: 72
Study 16398838 — intervention group
Group type: COMPARATOR
Intervention: Cow milk infant formula (CMF)
Number of subjects: 72
Study 16327967 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily visit from a communicator/facilitator
Number of subjects: 83
Study 16327967 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 83
Study 11590503 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment combinations of registered antiretroviral drugs (specific regimens not detailed)
Number of subjects: 0
Study 9262295 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow controlled-rate freezing
Number of subjects: 0
Study 9262295 — intervention group
Group type: COMPARATOR
Intervention: Rapid cooling
Number of subjects: 0
Study 8098293 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional factors and relative rest in the left lateral position
Number of subjects: 74
Study 8098293 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal control
Number of subjects: 74
Study 3303899 — intervention group
Group type: EXPERIMENTAL
Intervention: Bush potato (Ipomoea costata)
Number of subjects: 2
Study 3303899 — intervention group
Group type: COMPARATOR
Intervention: Potato (Solanum tuberosum)
Number of subjects: 2
Study 2789483 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1 microgram/kg prior to induction
Number of subjects: 60
Study 2789483 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 5 micrograms/kg prior to induction
Number of subjects: 60
Study 2789483 — intervention group
Group type: COMPARATOR
Intervention: Propofol alone (Control Group C)
Number of subjects: 60
Study 31858212 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum HEAL9
Number of subjects: 44
Study 31858212 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei 8700:2
Number of subjects: 44
Study 31858212 — intervention group
Group type: COMPARATOR
Intervention: Probi Defendum®
Number of subjects: 44
Study 30930034 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training in a game‐like format
Number of subjects: 150
Study 30930034 — intervention group
Group type: COMPARATOR
Intervention: Active control (computer games)
Number of subjects: 150
Study 29269937 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified rice endosperm protein (REP) supplementation (5 g/day for 4 weeks)
Number of subjects: 50
Study 29269937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 25693609 — intervention group
Group type: EXPERIMENTAL
Intervention: Revexepride 0.1 mg three times daily
Number of subjects: 480
Study 25693609 — intervention group
Group type: EXPERIMENTAL
Intervention: Revexepride 0.5 mg three times daily
Number of subjects: 480
Study 25693609 — intervention group
Group type: EXPERIMENTAL
Intervention: Revexepride 2.0 mg three times daily
Number of subjects: 480
Study 25693609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study 23300275 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 0
Study 23300275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20938767 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20 μg/day) for up to 24 months
Number of subjects: 758
Study 19245380 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 41
Study 19245380 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 41
Study 17124641 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 42
Study 17124641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 15695501 — intervention group
Group type: COMPARATOR
Intervention: Bolus 5-FU/LV (5-FU 425 mg/m2 i.v. and LV 20 mg/m2 i.v. bolus days 1-5 every 28 days for 6 months)
Number of subjects: 801
Study 15695501 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI 5-FU (300 mg/m2/day for 12 weeks)
Number of subjects: 801
Study 15695501 — intervention group
Group type: COMPARATOR
Intervention: Bolus 5-FU/LV
Number of subjects: 801
Study 15695501 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI 5-FU
Number of subjects: 801
Study 11933922 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 54
Study 11933922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 9337378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 615
Study 9337378 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion 100 mg
Number of subjects: 615
Study 7892806 — intervention group
Group type: EXPERIMENTAL
Intervention: Rogerian‐based peer facilitation skills training
Number of subjects: 104
Study 7892806 — intervention group
Group type: COMPARATOR
Intervention: Untrained college students taking a course in behavioral psychology
Number of subjects: 104
Study 2853055 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 0
Study 2853055 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 118551 25 mg
Number of subjects: 0
Study 2853055 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg + ICI 118551 25 mg
Number of subjects: 0
Study 2853055 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 0
Study 2853055 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg + ICI 118551 25 mg
Number of subjects: 0
Study 29294116 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 500
Study 29294116 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 500
Study 28604144 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 131
Study 28604144 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 131
Study 28604144 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 131
Study 25760887 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity LED light (3200 mW/cm(2)) cured for 6 seconds
Number of subjects: 34
Study 25760887 — intervention group
Group type: COMPARATOR
Intervention: Standard-intensity LED light (1200 mW/cm(2)) cured for 20 seconds
Number of subjects: 34
Study 23709132 — intervention group
Group type: EXPERIMENTAL
Intervention: Using a picture book during blood withdrawal
Number of subjects: 120
Study 23709132 — intervention group
Group type: EXPERIMENTAL
Intervention: No local anaesthesia with picture book
Number of subjects: 120
Study 23709132 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthesia
Number of subjects: 120
Study 21052022 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blocker or diuretic monotherapy
Number of subjects: 5152
Study 21052022 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blocker and/or diuretic treatment
Number of subjects: 5152
Study 21052022 — intervention group
Group type: COMPARATOR
Intervention: diltiazem treatment
Number of subjects: 5152
Study 18569138 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem 10 mg nightly for 14 nights (Control group)
Number of subjects: 32
Study 18569138 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom-oriented hypnotherapy, twice-a-week 1.5-hour sessions for 2 weeks (Intervention group)
Number of subjects: 32
Study 17135629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3234
Study 17135629 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle modification program
Number of subjects: 3234
Study 17135629 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 3234
Study 14575233 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ofloxacin and tinidazole
Number of subjects: 60
Study 11128874 — intervention group
Group type: EXPERIMENTAL
Intervention: Runners training in urban areas (n=69)
Number of subjects: 120
Study 11128874 — intervention group
Group type: COMPARATOR
Intervention: Runners training in rural areas (n=21)
Number of subjects: 120
Study 11128874 — intervention group
Group type: COMPARATOR
Intervention: Nonrunners (n=30)
Number of subjects: 120
Study 8806332 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue-type plasminogen activator (rt-PA) with adjunctive antithrombotic therapy (hirudin or heparin)
Number of subjects: 0
Study 2005228 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% triclosan mouthwash
Number of subjects: 16
Study 2005228 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% sodium lauryl sulphate (SLS) mouthwash
Number of subjects: 16
Study 2005228 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine mouthwash
Number of subjects: 16
Study 2005228 — intervention group
Group type: COMPARATOR
Intervention: saline control rinse
Number of subjects: 16
Study 6824189 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (Trental 400 tablets with 400 mg active ingredient)
Number of subjects: 24
Study 6824189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31075225 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based education (computer-based e-learning tool with clinical scenarios)
Number of subjects: 247
Study 31075225 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based education
Number of subjects: 247
Study 31075225 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (control)
Number of subjects: 247
Study 29724511 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-TT
Number of subjects: 0
Study 29724511 — intervention group
Group type: COMPARATOR
Intervention: MenC-CRM197
Number of subjects: 0
Study 29724511 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-TT (booster dose)
Number of subjects: 0